IPO - Petros Pharmaceuticals, Inc.

Form Type: 424B4

Filing Date: 2025-02-19

Corporate Action: Ipo

Type: New

Accession Number: 000141057825000164

Filing Summary: Petros Pharmaceuticals, Inc. is offering a total of 13,950,012 Units consisting of shares of common stock and warrants at a public offering price of $0.24 per Unit. Additionally, the offering includes 26,049,988 Pre-Funded Units each comprised of a pre-funded warrant, Series A and Series B Warrants. A significant portion of common stock related to these warrants (up to 156,049,988 shares) is also included in this offering. Holders of the Series A and Series B Warrants will be able to exercise their warrants following stockholder approval. The exercise price for both Series A and B Warrants is noted as $0.48 per share, with specific terms regarding the cashless option for Series B Warrants. The document outlines compliance with Nasdaq Capital Market regulations and includes risk factors associated with the offering. The company is an emerging growth company and intends to fulfill the conditions necessary to maintain its listing on the Nasdaq. The funds raised from this offering are expected to support ongoing development and operational needs.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: Update

Accession Number: 000141057825000137

Filing Summary: Petros Pharmaceuticals, Inc. has filed Amendment No. 3 to their Form S-1 registration statement with the SEC for an Initial Public Offering (IPO). This amendment refines details of the securities being offered to the public, outlining the company's intention to sell shares as soon as the registration statement becomes effective. It includes updated financial information, management discussions, and details concerning the registration process. The company's main office is located in New York, and it provides specified contact information for the registrant and its legal representatives, ensuring compliance with SEC regulations. The filing date indicates readiness for potential upcoming market actions regarding the IPO.

Document Link: View Document

Form Type: S-1MEF

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000110465925014398

Filing Summary: Petros Pharmaceuticals, Inc. has filed a registration statement under the Securities Act of 1933 with the SEC, designated as Form S-1MEF. This filing is made in connection with an increase in the proposed maximum aggregate offering price of the securities being offered by $1,600,000. The registration statement is a follow-up to a previous registration statement (File No. 333-284495) which was declared effective on February 14, 2025. The document includes necessary exhibits such as legal opinions and consents from independent registered public accounting firms. The company's principal executive offices are located in New York, and it is classified as a smaller reporting company and an emerging growth company. This offering aims to commence as soon as practicable after this statement becomes effective.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-13

Corporate Action: Ipo

Type: Update

Accession Number: 000141057825000122

Filing Summary: This document is an Amendment No. 2 to the Form S-1 Registration Statement submitted by Petros Pharmaceuticals, Inc. It details an update on their registration for the public offering of securities under the Securities Act of 1933. The filing specifies the registrant's principal executive offices in New York City and provides contact information for their legal representatives. It notes that the proposed sale to the public will commence after the registration statement becomes effective. The registration also confirms the company's intention for a delayed or continuous offering under Rule 415. This form aids investors by providing updated disclosures about the company's financials and operational setup as part of their IPO process.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-02-11

Corporate Action: Ipo

Type: New

Accession Number: 000110465925011313

Filing Summary: Petros Pharmaceuticals, Inc. has engaged Dawson James Securities, Inc. as the placement agent for its registration statement on Form S-1/A, filed under File No. 333-284495. The placement agent is requesting the SEC to make this registration statement effective on February 12, 2025, at 4:00 PM Eastern Time, ensuring timely fulfillment of all regulatory requirements pertaining to the offering. Additionally, Dawson James has distributed the Preliminary Prospectus dated February 10, 2025, to ensure adequate distribution in compliance with Rule 460 of the Securities Act. The document underscores the importance of compliance with Rule 15c2-8 under the Securities Exchange Act of 1934, emphasizing the preparation for the upcoming public offering activities.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: Update

Accession Number: 000141057825000108

Filing Summary: On February 10, 2025, Petros Pharmaceuticals, Inc. filed Amendment No. 1 to Form S-1 Registration Statement under the Securities Act of 1933. This amendment indicates the company's ongoing efforts to publicly offer securities, specifying details relating to the registration of shares intended for sale. It provides updated information on business operations, financial data, and share structure, intended to clarify the offerings to potential investors. The registration statement mentions the address of the principal executive offices, details about the president and contact people for legal matters, and confirms the anticipated date for the commencement of the public sale. Petros Pharmaceuticals is positioned as a Delaware corporation with significant ongoing operational activities in New York. The filing signifies an intention to go public, thereby classifying it as an IPO.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-24

Corporate Action: Ipo

Type: New

Accession Number: 000141057825000047

Filing Summary: Petros Pharmaceuticals, Inc. is registering securities under the Securities Act of 1933. This Form S-1 indicates the company's intention to conduct an initial public offering (IPO) of its common stock. Included in the filing is the basic information about the registrant, including its Delaware incorporation, address, and executive contact details. The expected date for the commencement of the public sale is shortly after the registration statement becomes effective. The form also reflects compliance with various regulatory requirements, including indications regarding delayed offerings and classifications of filer status.

Document Link: View Document